Title of Study: A Phase 1, First-in-Human, Ascending Dose Study of SAR441236, a Tri-specific Broadly Neutralizing Antibody, in Participants with HIV
What is a Broadly Neutralizing Antibody?
Antibodies are a type of protein that help the body fight infections. Antibodies develop naturally against HIV and attach to one part of the virus so that the body's immune sysem can try to attack it. However, HIV is a rapidly mutating virus that often outpaces antibodies. However, in the 90s, researchers found certain types of antibodies that were able to effectively target a wide range of HIV strains in individuals. These antibodies became the cornerstone for lab-manufactured versions called broadly neutralizing antibodies or bNAbs.
For a brief overview, please refer to the video below:
What is A5377?
The study will be investigating a specific bNAb named SAR441236, an antibod that has been manfuctured to attach to three parts of the HIV virus at the same time and to block the ability of the virus to infect more cells. The study will look at the following:
if one infusion of SAR441236 is safe and tolerable
if one infusion of SAR441236 can reduce the amount of HIV in a person's blood
if mutliple infusions (up to 4) are safe and tolerable and if they can reduce the amount of HIV in a person's blood more than receiving just one infusion
Information about the amount of SAR441236 in the blood over time
